Literature DB >> 27868033

Second line treatment of small cell lung cancer: more is better?

Michael S Humeniuk1, Michael John Kelley1.   

Abstract

Entities:  

Year:  2016        PMID： 27868033      PMCID： PMC5104621          DOI： 10.21037/atm.2016.10.68

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  15 in total

1.  A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer.

Authors:  Taofeek K Owonikoko; Madhusmita Behera; Zhengjia Chen; Chandar Bhimani; Walter J Curran; Fadlo R Khuri; Suresh S Ramalingam
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

2.  Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy.

Authors:  P E Postmus; H H Berendsen; N van Zandwijk; T A Splinter; J T Burghouts; W Bakker
Journal:  Eur J Cancer Clin Oncol       Date:  1987-09

3.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Authors:  Andrew G Nicholson; Kari Chansky; John Crowley; Ricardo Beyruti; Kaoru Kubota; Andrew Turrisi; Wilfried E E Eberhardt; Jan van Meerbeeck; Ramón Rami-Porta
Journal:  J Thorac Oncol       Date:  2015-12-24       Impact factor: 15.609

4.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

Authors:  J von Pawel; J H Schiller; F A Shepherd; S Z Fields; J P Kleisbauer; N G Chrysson; D J Stewart; P I Clark; M C Palmer; A Depierre; J Carmichael; J B Krebs; G Ross; S R Lane; R Gralla
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

5.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

Authors:  Kazumasa Noda; Yutaka Nishiwaki; Masaaki Kawahara; Shunichi Negoro; Takahiko Sugiura; Akira Yokoyama; Masahiro Fukuoka; Kiyoshi Mori; Koshiro Watanabe; Tomohide Tamura; Seiichiro Yamamoto; Nagahiro Saijo
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

6.  Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

Authors:  Joachim von Pawel; Robert Jotte; David R Spigel; Mary E R O'Brien; Mark A Socinski; Jörg Mezger; Martin Steins; Léon Bosquée; Jeffrey Bubis; Kristiaan Nackaerts; José M Trigo; Philip Clingan; Wolfgang Schütte; Paul Lorigan; Martin Reck; Manuel Domine; Frances A Shepherd; Shaoyi Li; Markus F Renschler
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

7.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Authors:  Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

8.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

9.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Authors:  Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

10.  Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.

Authors:  Koichi Goto; Yuichiro Ohe; Taro Shibata; Takashi Seto; Toshiaki Takahashi; Kazuhiko Nakagawa; Hiroshi Tanaka; Koji Takeda; Makoto Nishio; Kiyoshi Mori; Miyako Satouchi; Toyoaki Hida; Naruo Yoshimura; Toshiyuki Kozuki; Fumio Imamura; Katsuyuki Kiura; Hiroaki Okamoto; Toshiyuki Sawa; Tomohide Tamura
Journal:  Lancet Oncol       Date:  2016-06-14       Impact factor: 41.316
View more
  2 in total

1.  Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.

Authors:  Alessio Cortellini; Antonella Dal Mas; Katia Cannita; Guido Collina; Alessandro Parisi; Francesco Pavese; Giampiero Porzio; Lucilla Verna; Corrado Ficorella
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan.

Authors:  Marco D DiBonaventura; Bijal Shah-Manek; Karen Higginbottom; John R Penrod; Yong Yuan
Journal:  Ther Clin Risk Manag       Date:  2019-02-28       Impact factor: 2.423
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.